Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection

Bone Marrow Transplantation

Volumn 40, Issue 3, 2007, Pages 245-249

  de Fabritiis, P ^a   Spagnoli, A ^a   Di Bartolomeo, P ^b   Locasciulli, A ^c   Cudillo, L ^a   Milone, G ^d   Busca, A ^e   Picardi, A ^a   Scime R ^f   Bonini, A ^g   Cupelli, L ^a   Chiusolo, P ^h   Olivieri, A ⁱ   Santarone, S ^b   Poidomani, M ^d   Fallani, S ^j   Novelli, A ^j   Majolino, I ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SPIRITO SANTO HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d Ferrarotto Hospital   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g S MARIA NUOVA HOSPITAL   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ Ospedale Regionale Torrette   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CIPROFLOXACIN; FOSCARNET SODIUM; GANCICLOVIR; ITRACONAZOLE; LEVOFLOXACIN; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; LOADING DRUG DOSE; LUNG INFECTION; MALE; MYCOSIS; PRIORITY JOURNAL; RELAPSE; SECONDARY PREVENTION; VEIN OCCLUSION;

ADULT; ANTIFUNGAL AGENTS; DISEASE-FREE SURVIVAL; ECHINOCANDINS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547211213     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705720     Document Type: Article

References (23)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-364.
2. Marr K, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
4. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with haematological malignancies. Clin Infect Dis 2006; 42: 1584-1591.
5. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098-1103.
6. Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F. Aspergillosis prior to bone marrow transplantation. Infectious disease working party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group. Bone Marrow Transplant 1995; 16: 323-324.
7. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis: A contraindications to marrow transplantation? Blood 1994; 15: 2811-2814.
8. Cordonnier C, Maury S, Pautas C, Bastiè JN, Chehata S, Castaigne S et al. Secondary antifungal prophylaxis with vorizonazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-948.
9. Stute N, Kratochwille A, Zabelina T, Fehse N, Hassenpflug W, Panse J et al. Caspofungin is highly effective as secondary prophylaxis in allogeneic stem cell transplantation in patients with prior systemic or invasive fungal infections. Blood 2003; 102 (abstract 3636).
10. Onishi J, Meinz; M, Thompson J, Curotto J, Dreikorn S, Rosenbach M et al. Discovery of novel antifungal (1,3)-beta-d-glucan synthase inhibitors. Antimicrob Chemother 1999; 44: 368-377.
11. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, Lopez J, Arranz R, Cisneros JM et al. Safety of the concomitant use of Caspofungin and cyclosporin-A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
12. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: An international consensus. Clin Infect Dis 2002; 34: 7-14.
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representation of old estimators. Stat Med 1999; 18: 695-706.
14. Sable CA, Nguyen B-YT, Chodakewitz JA, DiNubile MJ. Safety and tolerability of Caspofungin in the treatment of fungal infections. Transplant Infect Dis 2002; 4: 25-30.
15. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
16. Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100: 3930-3934.
17. Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H et al. Chimerism and clinical outcome of 110 recipients of unrelated donor bone marrow transplant who underwent conditioning with low-dose, single exposure total body irradiation and cyclophosphamide. Blood 2005; 105: 3035-3041.
18. Yeghen T, Kibbler CC, Prentice HG, Berger LA, Wallesby RK, McWhinney PH et al. Management of invasive pulmonary aspergillosis in hematology patients: A review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31: 859-868.
19. Massard G. Role of surgery in the treatment of pulmonary aspergillosis. Rev Mal Respir 2005; 22: 466-472.
20. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-2936.
21. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of bacterial and fungal infections following non-myeloablative, compared to myeloablative allogeneic hematolopietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant 2002; 8: 512-520.
22. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematoloietic stem cell transplants after non-myeloablative conditioning. Blood 2003; 102: 827-833.
23. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006; 38: 327-337.